Eisai has obtained approval from the U.S. FDA for the early Alzheimer’s disease treatment with the anti-A\u03b2 antibody “Lecenvi\u00ae” in the form of the subcutaneous injection “LEQEMBI IQLIK\u00ae” and plans to launch it in the United States in late August 2026. The impact on the earnings forecast for the fiscal year ending March 2027 is expected to be minimal.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4523","jir_company_name":"Eisai Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-07-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4523-20260714-01.pdf","jir_short_summary":"Eisai has obtained approval from the U.S. FDA for the early Alzheimer's disease treatment with the anti-A\u03b2 antibody \"Lecenvi\u00ae\" in the form of the subcutaneous injection \"LEQEMBI IQLIK\u00ae\" and plans to launch it in the United States in late August 2026. The impact on the earnings forecast for the fiscal year ending March 2027 is expected to be minimal.","jir_summary":"### Overview of Performance\nEisai has obtained approval from the U.S. FDA for the early Alzheimer's disease treatment with the anti-A\u03b2 antibody \"Lecenvi\u00ae\" in the form of the subcutaneous injection \"LEQEMBI IQLIK\u00ae\" and plans to launch it in the United States in late August 2026. This approval is based on multiple clinical trials confirming safety and efficacy, with sustained effects observed in long-term extension studies. The approval will improve the convenience of outpatient administration, expand treatment options, and reduce patient burden. The impact on the earnings forecast for the fiscal year ending March 2027 is expected to be limited.\n\n### Future Outlook and Impact on Investors\nWith the approval of this new drug, Eisai aims to expand the dementia treatment market and promote home medical care. The innovative administration method is expected to improve treatment access and optimize medical resources, positioning it as part of the company's long-term growth strategy. Financial support programs will also be enhanced to assist patient access to medications. Ongoing sales development and accumulation of clinical data are anticipated to stabilize and grow the business, ensuring long-term growth.","jir_financial_highlights":"Impact on earnings forecast: Unknown (Minimal)","jir_category":"","jir_hashtags":"#Eisai, #IRRelated, #JapaneseStocks","jir_key_figures":"Approval date: 2026-07-13\nScheduled launch date: late August 2026\nImpact on earnings forecast: Minimal","jir_meta_title":"\u3010Eisai\u3011Anti-Alzheimer's Drug Approval | July 2026","jir_meta_description":"Eisai has obtained approval from the U.S. FDA for the anti-A\u03b2 antibody \"Lecenvi\u00ae\" as an early treatment, with plans to launch in the U.S. in August 2026. The impact on performance is expected to be minimal.","jir_og_title":"\u3010Eisai\u3011Anti-Alzheimer's Drug Approval | July 2026","jir_og_description":"Eisai has obtained approval from the U.S. FDA for the anti-A\u03b2 antibody \"Lecenvi\u00ae\" and plans to launch in the U.S. in August 2026. The impact on performance is expected to be limited.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7482,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-80143","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n